Investigation abut the relationship between systemic sympathetic nerve activity and use of SGLT2 inhibitor in patients with type2 diabetes mellitus.

Investigation abut the relationship between systemic sympathetic nerve activity and use of SGLT2 inhibitor in patients with type2 diabetes mellitus. - Investigation abut the relationship between systemic sympathetic nerve activity and use of SGLT2 inhibitor in patients with type2 diabetes mellitus.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026335

Enrollment

Registered

2017-03-01

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetes mellitus

Interventions

Taking dapagliflozin 5mg/day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type2 diabetes mellitus patients HbA1c 7-10%

Exclusion criteria

Exclusion criteria: Patients who can't indicate one's intention History of myocardial infarction within 3 months before. Complicated with lung disease renal failure( eGFR<45)

Design outcomes

Primary

Measure	Time frame
The comparison of muscle sympathetic nerve activity between baseline and 24 week after implementation of dapagliflozin therapy.	—

Secondary

Measure	Time frame
To compare the difference of primary outcome between patients complicated with heart failure and patients without heart failure. To compare the difference of echocardiographic parameters(EF,E/E',etc.) and labor data(BNP,etc.) between baseline and 24 week after implementation of dapagliflozin therapy.	—

Countries

Japan

Contacts

Public ContactTakuto Hamaoka

Kanazawa university Graduate school of advanced preventive medical science, system biology

tokuta114@yahoo.co.jp076-265-2233

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026